Mindbloom vs. Joyous: Comparing Ketamine Therapy Programs

Mindbloom vs. Joyous at a Glance

Choosing the best at home ketamine therapy requires understanding the different approaches providers take to patient care. This comparison covers the treatment philosophies, support models, and clinical evidence behind Mindbloom and Joyous to help you make an informed decision.

At a core level, Mindbloom delivers a clinician-supervised care model where ketamine is one component of a guided therapeutic process. Joyous delivers a low-cost daily microdosing subscription that relies primarily on asynchronous, app-based check-ins.

Both providers operate within established medical frameworks. Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the World Health Organization's List of Essential Medicines since 1985.

Both companies prescribe ketamine off-label for mental health conditions. This is a widespread and legally accepted medical practice in the United States.⁸

How Mindbloom Works

Mindbloom is a guided at-home ketamine therapy provider offering structured programs of 6, 12, or 18 sessions. Ketamine is delivered as part of a complete care model that includes clinician consults, guide coaching, integration support, and community access.

The process begins with an initial clinical evaluation via telehealth to create a personalized treatment plan. During a session, you use either sublingual tablets or subcutaneous injectables while a peer treatment monitor is required to be present.

Treatment frequency is personalized based on clinical guidance. Sessions may be more frequent initially to build therapeutic momentum, then adjusted based on your progress.

Mindbloom has facilitated over 700,000 clinician-supervised sessions to date. The company has published two peer-reviewed studies in the Journal of Affective Disorders evaluating the safety and effectiveness of its protocol at scale.

It is also the only at-home ketamine provider offering subcutaneous administration in addition to sublingual tablets.

Mindbloom Pros

• Published evidence: Peer-reviewed outcomes data published on its own specific protocol.
• Administration options: Both sublingual tablets and subcutaneous injectables are available.
• High-touch support: Includes 1:1 guide coaching, unlimited Group Integration Circles, and unlimited guide messaging.
• Comprehensive tools: Access to the Mindbloom app with 10+ therapeutic programs, custom soundscapes, and a physical Bloombox toolkit.
• Value: Approximately 60% more affordable per session than traditional IV ketamine clinics.

Mindbloom Cons

• Upfront investment: Higher initial cost than a monthly microdosing subscription.
• Support requirement: A peer treatment monitor must be present during every session.
• Time commitment: Sessions require dedicated time and a post-session transition period, rather than acting as a background treatment.
• Availability: Not currently available in all 50 states.

Mindbloom Pricing and Programs

Mindbloom offers different program tiers, including a New Client 6-session program and Returning Client programs of 6, 12, or 18 sessions. Because the Mindbloom cost varies based on the selected program, prospective clients should check the company's website for current pricing.

While Mindbloom does not currently accept insurance directly, HSA or FSA funds may often be used to cover treatment costs.

How Joyous Works

Joyous is an at-home ketamine provider that utilizes a daily low-dose model, often referred to as microdosing or psycholytic therapy. The medication is delivered via sublingual troches on a monthly subscription basis.

This approach is designed to provide consistent, mildly perceptual effects and generally aims for less pronounced dissociative intensity than session-based therapeutic dosing. The Joyous model begins with an online intake and clinician evaluation.

You are prescribed low-dose troches, typically starting around 10 to 15mg, which are titrated up based on daily text-based check-ins. Support is primarily asynchronous and app-based.

You report your daily mood via text and clinicians adjust doses accordingly, without scheduled video coaching sessions or group integration. Joyous positions itself as an affordable, accessible entry point into ketamine therapy.

The monthly subscription model and daily dosing cadence differ fundamentally from session-based therapeutic programs. To date, Joyous has not published peer-reviewed research evaluating clinical outcomes from its own specific protocol.

Joyous Pros

• Low monthly cost: A flat fee of $129 per month includes both medication and app-based support.
• Daily routine: Dosing is designed to minimize disruption to daily functioning.
• No monitor needed: A peer treatment monitor is not required during administration.
• Accessibility: Provides a low barrier to entry for ongoing use.

Joyous Cons

• Lack of protocol data: No published peer-reviewed outcomes data evaluating its own specific model.
• Minimal human support: Relies on asynchronous text check-ins rather than live coaching or video consults.
• Integration model: Joyous centers support on asynchronous app-based check-ins rather than integration coaching or group support as a standard feature.
• Administration method: Joyous offers sublingual troches as its sole administration option.
• Long-term questions: Daily dosing raises questions about long-term use patterns that have not been extensively studied in peer-reviewed literature under this specific model.

Joyous Pricing and Subscription

The Joyous cost is structured as a $129 monthly subscription. This recurring fee covers the medication, daily text-based check-ins, and asynchronous clinician oversight via their app.

This ongoing subscription model contrasts with per-session program pricing, making it a different financial commitment over time.

Mindbloom vs. Joyous Key Differences

Now that both models are outlined, it is helpful to compare them across the dimensions that matter most when choosing a provider. Each subsection below addresses a specific axis of comparison to help you evaluate your options.

Clinical Evidence and Published Research

Published outcomes data on a provider's own protocol demonstrates that they have subjected their specific care model to independent peer-reviewed scrutiny. It shows accountability and transparency about what their exact approach delivers, rather than relying solely on general ketamine research.

Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy. In a peer-reviewed Mindbloom study of 11,441 patients, 89% of Mindbloom clients reported improvement in their symptoms.

Joyous references general ketamine literature but has not published peer-reviewed research evaluating outcomes from its own daily low-dose protocol. When evaluating online ketamine therapy reviews and providers, published research on the provider's own model is a meaningful differentiator.

Care Model and Support Structure

A care model encompasses the full system of clinical oversight, therapeutic support, and integration surrounding the medication itself.

• Mindbloom's approach: Provides clinician consults, 1:1 guide coaching sessions, unlimited Group Integration Circles, and requires a peer treatment monitor during sessions.
• Joyous's approach: Relies on an initial clinician evaluation followed by daily text-based mood check-ins and asynchronous dose adjustments.

The distinction lies between a clinically managed therapeutic program versus a medication-delivery subscription with automated monitoring. Different individuals may value different levels of support depending on their clinical needs.

Administration Methods and Dosing

Mindbloom offers two administration routes. You can choose sublingual tablets held between the cheek and gum, or subcutaneous injectables self-administered in the abdomen.

Doses are sub-anesthetic and clinician-determined based on your individual clinical needs. Joyous uses sublingual troches exclusively.

These are administered daily at very low doses intended to be sub-perceptual or mildly perceptual. It is important to note that safety is a function of clinical supervision, screening, and structured protocols, not dose size alone.⁹

These two approaches represent fundamentally different treatment philosophies. One uses periodic therapeutic doses within a dedicated session, while the other uses daily low doses intended as background support.

Treatment Frequency and Scheduling

Mindbloom programs are built as 6, 12, or 18 sessions with personalized treatment frequency. Sessions may be more frequent at the outset to establish therapeutic momentum.

Each session requires a peer treatment monitor and time for a post-session transition. Joyous utilizes a daily model where the troche is taken once per day as part of a continuous regimen.

Mindbloom's model is session-based and time-bounded with a defined program arc. Joyous's model is continuous and open-ended, designed not to require dedicated session time or a support person.

Cost, Insurance, and Value

Mindbloom utilizes program-based pricing that varies by session count. Joyous charges a flat monthly subscription fee.

Neither provider currently accepts insurance directly, though HSA or FSA funds may be eligible for both. When evaluating cost, consider what is included in the price.

Mindbloom's price encompasses clinician consults, guide coaching, integration circles, the Bloombox, and app access. Joyous's price covers medication and text-based check-ins.

The lowest sticker price does not necessarily represent the best overall value for your specific clinical needs.

Safety Protocols and Clinical Screening

Safety protocols in at-home ketamine therapy encompass screening, monitoring, in-session safety measures, and escalation procedures. Ketamine can temporarily increase blood pressure and heart rate during a session.¹⁰

Individuals with uncontrolled hypertension may not be appropriate candidates, which is why cardiovascular screening is a critical part of the intake process.⁹

• Mindbloom's screening: Conducts clinical screening via telehealth consults to evaluate medical history and contraindications, and requires a peer treatment monitor to be present during every session.
• Joyous's screening: Conducts an initial online evaluation and monitors patients via daily text check-ins, without requiring an in-session support person.

Both providers include medical screening to evaluate appropriateness for care. The models differ primarily in the depth and frequency of clinical touchpoints and their specific in-session safety requirements.

Mindbloom Outcomes From Published Research

Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy to date. Both studies were published in the Journal of Affective Disorders and evaluated Mindbloom clients using validated clinical instruments.

Direct comparisons across treatment modalities should be interpreted with caution due to differences in study design, patient populations, and outcome measures.

• Depression: In a peer-reviewed Mindbloom study of 11,441 patients, 89% of Mindbloom clients reported improvement in their symptoms, and 56.4% met criteria for response. Mindbloom's reported depression response rates (56–63%) exceed those reported in selected SSRI antidepressant studies and are comparable to or modestly exceed those reported in selected IV ketamine studies.¹ ⁴ ⁶
• Anxiety: In Mindbloom's published anxiety outcomes data, 89% of participants reported improvement in their symptoms, and 56.1% met criteria for anxiety response. Mindbloom's reported anxiety response rate (56.1%) is comparable to or exceeds response rates reported in selected psychotherapy trials for anxiety disorders.²
• PTSD: In a real-world analysis of 374 Mindbloom PTSD program completers, 92.2% reported symptom improvement, and 79.7% met criteria for response. Mindbloom's reported response rate (79.7%) exceeds response rates reported in randomized trials of prolonged exposure therapy for PTSD.³ ⁵
• Sleep: Participants experienced an average 49% reduction in sleep disturbance severity, with a 77% response rate. [CITATION NEEDED]
• Safety: In Mindbloom's published outcomes data, side effects were reported in approximately 4–5% of participants, with serious adverse events in <0.1% and a discontinuation rate of 0.4%.¹

These results build on decades of clinical research, though individual results may vary.

Should You Choose Mindbloom or Joyous?

Deciding between these two providers depends entirely on your treatment goals, budget, and preferred level of clinical support.

Mindbloom may be a better fit if:

• You want a clinically managed therapeutic program with defined sessions and a clear arc.
• You value 1:1 coaching and group integration support to help sustain progress.
• You want a provider with published peer-reviewed outcomes data on its own protocol.
• You are interested in subcutaneous administration for more consistent dosing.
• You prefer a high-touch care model with clinical oversight throughout the process.

Joyous may be a better fit if:

• You are looking for the lowest monthly cost available.
• You prefer a daily routine that does not require dedicated session time.
• You are comfortable with asynchronous app-based support rather than live coaching.
• You want a gentle, sub-perceptual approach with less emphasis on the more immersive dissociative experience sometimes associated with session-based dosing.

If you are ready to explore guided at-home ketamine therapy backed by published research and a comprehensive care model, you can begin your assessment with Mindbloom.

Safety and Medical Disclaimer

IMPORTANT SAFETY INFORMATION
‍Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary.Full safety information: www.mindbloom.com/safety-information‍

‍OFF-LABEL USE DISCLOSURE
‍Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.